Table 1 Characteristics of the patients participating in the Clinical Study
Pt # | Sex | Age | Stage | Mts Site | MN Cells obtained (×109cells) | Dose of DC/Apo-Nec (×106cells) | No. Vacc | Clin. Evolution (12/1/07) | IL-10 Promoter Genotype |
|---|---|---|---|---|---|---|---|---|---|
1 | F | 42 | III | LN | 3.5 | 5 | 4 | P (10 m) | AA |
2 | F | 57 | III | ND | 3.6 | 5 | 4 | NED (62 m+) | AG |
3 | M | 32 | III | ND | 3.3 | 5 | 4 | NED (43 m+) | AA |
4 | F | 17 | III | ND | 4.4 | 5 | 4 | NED (53 m+) | AG |
5 | M | 56 | IV | L,SC | 5 | 10 | 4 | P (4 m) | AA |
6 | M | 60 | III | ND | 1.5 | 3 | 4 | NED (45 m+) | AA |
7 | M | 27 | IV | SC | 4.2 | 10 | 2 | WP (1 m) | AA |
8 | M | 26 | IV | ND | 3.6 | 10 | 4 | P (7 m) | AA |
9 | F | 42 | III | ND | 7.5 | 15 | 4 | NED (79m+) | AG |
10 | M | 34 | IV | LN | 6.2 | 15 | 4 | P (11 m) | AG |
11 | M | 44 | IV | L | 4.7 | 15 | 4 | P (4 m) | AG |
12 | M | 56 | III | ND | 8 | 15 | 4 | NED (33m+) | AG |
13 | M | 47 | IIC | ND | 9.3 | 20 | 4 | NED (34 m+) | AA |
14 | M | 30 | III | ND | 7.5 | 20 | 4 | NED (47 m+) | GG |
15 | M | 52 | IV | LN | 6 | 20 | 4 | P (10 m) | AA |
16 | F | 57 | IV | SC | 8.2 | 20 | 4 | P(6 m) | AA |